Holen Sie sich die Stockscreener-App
0.7146
10.96%
0.0706
Handel nachbörslich:
.74
0.0254
+3.55%
Schlusskurs vom Vortag:
$0.644
Offen:
$0.635
24-Stunden-Volumen:
166.19K
Relative Volume:
0.31
Marktkapitalisierung:
$2.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.07M
KGV:
-0.0511
EPS:
-13.99
Netto-Cashflow:
$-12.56M
1W Leistung:
+3.76%
1M Leistung:
-10.54%
6M Leistung:
-79.17%
1J Leistung:
-87.58%
1-Tages-Spanne:
$0.60
$0.7429
1-Wochen-Bereich:
$0.60
$0.7429
52-Wochen-Spanne:
$0.60
$9.65
Palisade Bio Inc Stock (PALI) Company Profile
Firmenname
Palisade Bio Inc
Sektor
Branche
Telefon
(858) 704-4900
Adresse
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Vergleichen Sie PALI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
0.7146 | 2.80M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Palisade Bio Inc Aktie (PALI) Neueste Nachrichten
PALI stock plunges to 52-week low, touches $0.64 amid market challenges - Investing.com Australia
Palisade Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PALI stock plunges to 52-week low, hitting $0.74 By Investing.com - Investing.com South Africa
PALI stock plunges to 52-week low, hitting $0.74 - Investing.com
Palisade Bio Inc expected to post a loss of $1.99 a shareEarnings Preview - TradingView
Palisade Bio (PALI) Expected to Announce Earnings on Tuesday - Defense World
Palisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trial - Yahoo
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Palisade Bio Begins Dosing Ulcerative Colitis Patients in PALI-2108 Trial -March 14, 2025 at 08:58 am EDT - Marketscreener.com
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewswire
Palisade Bio Reports Encouraging Preliminary Safety and Tolerability Data for PALI-2108 in Phase 1a/b Study for Ulcerative Colitis - Nasdaq
Palisade Bio's UC Treatment Advances: Zero Serious Events as Patient Trial Launches - StockTitan
Palisade Bio to present ulcerative colitis treatment data By Investing.com - Investing.com Australia
Palisade Bio Announces Two Abstracts Selected to be - GlobeNewswire
Palisade Bio to present ulcerative colitis treatment data - Investing.com
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 - Yahoo Finance
Rokos Group Seeking Chief Medical Officer for Alameda Health System - Hunt Scanlon Media
Palisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Palisade Bio Participates in Virtual Investor 'What This Means” Segment - The Manila Times
Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Can Palisade Bio's Promising UC Drug Candidate Transform Treatment Options? - StockTitan
Palisade Bio secures Canadian tax credit for drug study By Investing.com - Investing.com Nigeria
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) - The Manila Times
Palisade Bio secures Canadian tax credit for drug study - Investing.com India
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from - GlobeNewswire
Canadian Government Backs This Promising Ulcerative Colitis TreatmentWhat's Behind the $1.39M Investment? - StockTitan
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Autonomix Medical, Inc. Participates in the Virtual Investor 'Top 5 for '25” On-Demand Conference - The Manila Times
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand - Big News Network
Inside Palisade Bio's Ambitious 2025 Roadmap: 5 Critical Growth Drivers Revealed - StockTitan
Virtual Investor “Top 5 for ’25” Conference Hosted by JTC Now Available On-Demand - Idaho Statesman
PALI stock plunges to 52-week low, touches $1.34 - MSN
PALI-2108 colon-activated prodrug prevents ulcerative colitis progression - BioWorld Online
PALI’s Q2 earnings predictions: What the experts say - US Post News
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewswire
Q4 Earnings Roundup: Children's Place (NASDAQ:PLCE) And The Rest Of The Apparel Retailer Segment - The Globe and Mail
Palisade Bio's UC Drug Outperforms Standard Treatments in Preclinical StudiesKey Data Unveiled - StockTitan
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
Reviewing Protara Therapeutics (NASDAQ:TARA) and Palisade Bio (NASDAQ:PALI) - Defense World
JPMorgan Chase & Co. Purchases Shares of 8,200 Palisade Bio, Inc. (NASDAQ:PALI) - Defense World
PALI stock touches 52-week low at $1.32 amid market challenges - Investing.com
PALI stock touches 52-week low at $1.32 amid market challenges By Investing.com - Investing.com South Africa
Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress - The Manila Times
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress - GlobeNewswire
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - The Manila Times
Palisade Bio CEO to Present at Webull Healthcare Investment Webinar This January - StockTitan
Palisade Bio reports positive data for UC drug trial - MSN
Palisade Bio begins MAD cohorts of Phase Ia/b ulcerative colitis therapy trial - Yahoo! Voices
Palisade Bio reports positive data for UC drug trial By Investing.com - Investing.com Australia
Finanzdaten der Palisade Bio Inc-Aktie (PALI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Palisade Bio Inc-Aktie (PALI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wei Binxian | Director |
Nov 21 '24 |
Option Exercise |
0.00 |
388 |
0 |
855 |
| Wei Binxian | Director |
Jun 11 '24 |
Option Exercise |
0.00 |
465 |
0 |
467 |
| Williams Donald Allen | Director |
Jun 11 '24 |
Option Exercise |
0.00 |
340 |
0 |
340 |
| Jones Mitchell Lawrence | Chief Medical Officer |
May 28 '24 |
Option Exercise |
0.00 |
4,290 |
0 |
4,313 |
| Finley John David | CEO, CFO, Director |
May 28 '24 |
Option Exercise |
0.00 |
7,068 |
0 |
14,079 |
| Williams Donald Allen | Director |
May 28 '24 |
Buy |
4.86 |
1,000 |
4,863 |
1,000 |
| Finley John David | CEO, CFO, Director |
May 24 '24 |
Buy |
4.81 |
1,000 |
4,810 |
8,437 |
| Jones Mitchell Lawrence | CEO, CFO, Director |
May 06 '24 |
Option Exercise |
0.00 |
460 |
0 |
880 |
| Finley John David | CEO, CFO, Director |
May 06 '24 |
Option Exercise |
0.00 |
443 |
0 |
6,832 |
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):